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Background: Gene expression signatures have been commonly used as diagnostic and prognostic markers for
cancer subtyping. However, expression signatures frequently include many passengers, which are not directly
related to cancer progression. Their upstream regulators such as transcription factors (TFs) may take a more critical
role as drivers or master regulators to provide better clues on the underlying regulatory mechanisms and
therapeutic applications.
Results: In order to identify prognostic master regulators, we took the known 85 prognostic signature genes for
colorectal cancer and inferred their upstream TFs. To this end, a global transcriptional regulatory network was
constructed with total >200,000 TF-target links using the ARACNE algorithm. We selected the top 10 TFs as
candidate master regulators to show the highest coverage of the signature genes among the total 846 TF-target
sub-networks or regulons. The selected TFs showed a comparable or slightly better prognostic performance than
the original 85 signature genes in spite of greatly reduced number of marker genes from 85 to 10. Notably, these
TFs were selected solely from inferred regulatory links using gene expression profiles and included many TFs
regulating tumorigenic processes such as proliferation, metastasis, and differentiation.
Conclusions: Our network approach leads to the identification of the upstream transcription factors for prognostic
signature genes to provide leads to their regulatory mechanisms. We demonstrate that our approach could identify
upstream biomarkers for a given set of signature genes with markedly smaller size and comparable performances.
The utility of our method may be expandable to other types of signatures such as diagnosis and drug response.
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With advances in genome-wide gene expression tech-
nologies, classification of cancer subtypes based on
expression signatures is widespread and results in many
biomarkers for various cancers. This molecular signature-
based approach is more objective and reproducible
than conventional methods based on clinicopathological
features. There are plenty of clinical applications that
are actively being sought [1-3]. Some of these are
already in commercial use [4,5] for selecting treatment
strategies and predicting prognosis. In spite of the* Correspondence: sungkim@snu.ac.kr
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reproduction in any medium, provided the oradvantages and successful applications, the identifica-
tion of causal oncogenic pathways and driver-regulators
remains a challenge [6]. The main bottleneck is that
expression signatures normally consist of cancer drivers
and passengers with the latter as not directly related to
cancer progression. The reason for this is that passengers
frequently take the majority of the signature gene and an
accurate discrimination of cancer drivers from passengers
becomes a key subject in cancer genomic studies.
Regulatory network modeling has been widely used for
a systematic understanding of disease progression at the
molecular level, particularly for cancer (comprehensively
reviewed by Peer and Hacohen) [7]. Recently, Carro et al.
applied a reverse engineering method for context-specific
transcriptional regulatory networks to 176 gene expression
profiles from high-grade glioblastoma (HGG) patients.
Two TFs (C/EBPβ and STAT3) were successfully iden-
tified as master regulators and control ‘mesenchymal’. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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epithelial-to-mesenchymal transition and neo-angiogenesis
[8]. They applied the ARACNE algorithm for global
reconstruction of regulatory network [9], where directed
or causal TF-target relationship was extracted from
measuring conditional mutual information. Then, the
regulatory TFs for the mesenchymal signature genes
were inferred from the use of master regulator analysis
(MRA) together with or without stepwise linear regression
method (SLR). This provides an exemplary case to
pinpoint upstream regulators of known cancer signatures
as cancer drivers and, accordingly, to a promising
therapeutic target. Further, this strategy also provides a
chance to develop biomarkers of even smaller sizes
than the original signature, which is highly desirable for
practical usage in terms of cost and interpretation.
In this study, we used Carro et al. [8] as the framework
of our analysis and applied the same method to colorectal
cancer with only minor modifications. Colorectal cancer
is one of the most commonly diagnosed cancers and
the fourth leading cause of cancer-related death in
males and the third in females worldwide [10]. Several
research groups have identified prognostic molecular
signatures that use genome-wide gene expression pro-
files of colorectal cancer patients [11-13]. Recently, Oh
et al. classified 177 colorectal patients into two groups
from the use of global gene expression profiles and
extracted 85 signature genes (114 probe set) that were
differentially expressed between the two groups. This
gene signature shows a good prognostic ability to dis-
criminate colorectal cancer patients between good and
poor prognostic groups with high accuracy [14]. We
reasoned that the upstream regulators or transcription
factors (TFs) of these prognostic signatures might take
a critical role as driver or master regulator to provide clues
on the underlying regulatory mechanisms and therapeutic
applications. Here, we applied a reverse engineering
algorithm to reconstruct an unbiased transcriptional
network from colorectal cancer. Using this network,
the upstream regulators of the prognostic signatures
were identified and tested for their utility as prognostic
markers. Our network models provide clues on the
potential regulatory mechanisms for these upstream
regulators that may cause prognostic differences.
Results and discussion
Overview of the analytic procedure
Our analytic procedure followed that of Carro et al. [8].
In the study, a global regulatory network was inferred
from high-grade glioblastoma (HGG). The difference
was that we focused on modeling regulatory networks
only for the 85 prognostic marker genes in colorectal
cancer reported by Oh et al. [14]. From the use of the
network model, we then extracted their upstreamregulators or TFs and tested their prognostic ability in
comparison with the original 85 signature genes.
As the detail of mathematical formulation is described
from the previous work [9] and the methods section,
we briefly summarize our overall procedures (Figure 1).
Once a global regulatory network was constructed using
the ARACNE algorithm, regulons or TF targets are
extracted for all candidate TFs. Top candidate TFs were
chosen based on the coverage of signatures as downstream
regulated genes (= regulons). This procedure or master
regulator analysis (MRA) is equal to conventional gene
set analysis (GSA) based on the Fisher exact test. Alter-
natively, we applied a stepwise linear regression method
(SLR) for each signature gene and its expression was
modeled using a minimal set of candidate TFs. In our
case, SLR was used only to filter out weak TF-target
relations in each regulon and to keep the most obvious
interactions modeled by simple linear equations. In con-
trast, Carro et al. expanded the candidate TFs before the
application of SLR by including additional 52 TFs with
their promoter sequences enriched among the signature
genes [8]. Therefore, our study is more suitable to evaluate
whether a regulatory model can successfully identify key
upstream regulators (e.g. prognostic markers) purely based
on expression profiles without depending on external
knowledge.
Construction of regulatory networks and identification of
upstream regulators for prognostic signatures
First, we took the 177 expression profiles from colon
cancer patients from Moffit Cancer Center (Moffit cohort,
n = 177 [12]). They were also used to extract the 85
prognostic signature genes for colorectal cancer. Then
the ARACNE algorithm was applied to infer a global
transcriptional network. In total, we inferred 155,818
TF-target interactions between 834 TFs and 17,065 target
genes in the context of colorectal cancer (Figure 1A).
In total, 834 regulons were extracted, each consisted of a
TF and its target genes (Figure 1B). For the 834 regulons,
we applied MRA, which tests significant overlap between
the regulons and the 85 signature genes (Figure 1C).
MRA identified 67 TFs, of which targets significantly
overlap with the signature at a false discovery rate
(FDR) < 0.05 (Additional file 1: Table S1). The 67 TFs
collectively regulate 84 of the 85 signature genes
(Figure 1D).
We further applied SLR to the regulons identified by
MRA. In this step, the expression level of each signature
gene was modeled by the linear combination of the ex-
pression levels of its upstream TFs in the network. The
reason that the SLR method tries to minimize the number
of TFs in modeling the expression level of each signature
gene is that only the TFs showing strong linear correlation
tend to remain in the final regression model. Accordingly,
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Figure 1 Overall pipeline of upstream regulator inference. (A) Global regulatory network modeling using ARACNE. (B) Regulon extraction for
each TF. (C) Master regulator analysis (MRA) selects the TFs showing a significant overlap with the prognostic signature genes (D) Extraction of
top 10 TFs by the signature coverage of MRA derived regulons (E) Stepwise linear regression (SLR) for edge filtering and extraction of top 10 TFs
by the signature coverage of MRS + SLR derived regulons.
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effective TF-target interactions (Figure 1E).
The TFs were ranked by the order of signature coverage,
i.e. the number of signature genes regulated by corre-
sponding TF. In MRA and MRA + SLR method, the
first 10 TFs covered most of the 85 signature genes. In
MRA, the coverage the top 10 TFs was 83 out of the 85
signature genes with the average number of target
genes per TF = 8.3. In case of MRA + SLR, the coverage
was 71 out the 85 genes with 7.1 target genes per TF.
These two sets of top 10 TFs by MRA and MRA + SLR
method were chosen as candidate upstream regulators
for further analysis and named as TFMRA and TFMRA+SLR,
respectively (Table 1). The two TF sets largely agreed
to each other with 7 TFs in common (i.e. PLAGL2,
PRRX1, SPDEF, SATB2, ASCL2, HIF1A, and TCF7).
Three TFs were specific for MRA (BCL6, TFCP2L1,
and FOSL2) and MRA + SLR (AEBP1, GTF2IRD1, and
TCEAL1), respectively. We constructed two versions of
regulatory networks between the top 10 upstreamregulators (TFMRA and TFMRA+SLR) and their downstream
targets among the 85 signature genes. Additional file 1:
Table S4 lists the downstream signature genes of each
TF. Figure 2 and Additional file 2: Figure S1 visualizes
networks for TFMRA and TFMRA+SLR. Notably, some
transcription factors were linked by positive or negative
regulatory interactions. ASCL2 was positively regulated
by two TFs (PLAGL2 and TCF7) and negatively by
SPDEF to suggest a higher order structure among the
upstream regulators. Many of the prognostic signature
genes were co-regulated by several TFs, e.g. ACSL6 by
four TFs (TCF7, TCEAL1, SATB2, and HIF1A) and
VAV3 by three TFs (GTF2IRD1, SATB2, and TCF7).
Prognostic effect analyses for the upstream regulators
identified by MRA and MRA + SLR
The 85 signature genes consisted of 34 low-risk and 51
high-risk marker genes that were significantly up and
down-regulated, respectively, in the patient group of
better survival [14]. Accordingly, we assigned the prog-







MRA1 MRA + SLR2
Rank Signature coverage FDR3 Rank Signature coverage
PLAGL2 + 575 1 32 7.73E-25 1 20
PRRX1 - 327 4 22 2.10E-18 2 17
SPDEF - 304 6 18 6.50E-14 3 16
SATB2 + 264 3 23 1.28E-21 4 15
ASCL2 + 537 2 28 6.12E-21 5 11
AEBP1 - 465 15 12 2.21E-05 6 10
TCF7 + 408 9 15 9.47E-09 7 9
TCEAL1 + 276 16 10 1.08E-05 7 9
HIF1A - 371 4 22 2.58E-17 7 9
GTF2IRD1 + 429 16 10 0.000334 7 9
BCL6 - 455 7 16 4.50E-09 11 8
TFCP2L1 + 364 9 15 2.26E-09 14 7
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(−) class that depends on whether the majority of the
downstream target genes are regulated in favor of
expressing low-risk or high-risk signatures. First, we
calculated Spearman’s rank correlation between each
TF and its downstream signature genes. The regulatory
mode was determined by the sign of Spearman’s rank
correlation between a TF and its target, where positive
correlation indicated ‘activation’ and negative did ‘repres-
sion’. The prognostic effect of a TF was assigned positive
(+) if the sum of activated low-risk and repressed high-
risk genes was more than half among its downstream
signature genes. Among the 67 TFs selected by MRA,
the prognostic effect of the 30 TFs was positive with
the remaining 37 TFs being negative (Additional file 1:
Table S3).
We focused on the top 10 TFs in TFMRA and TFMRA+SLR
and asked whether their prognostic effect is consist-
ently observed across different data sources. However,
the Moffit cohort used for network construction by
ARACNE, we took another set of gene expression
profiles from Royal Melbourne Hospital (Melbourne
cohort, n = 95) [11]. Positive prognostic effect was
observed in five out of the 10 TFs in TFMRA and four
in TFMRA+SLR in the Moffit cohort (Figure 3A). The
rest five and six TFs showed negative prognostic effect,
respectively. We observed exactly the same trend for
all the TFs tested in the Melbourne cohort to suggest
that their regulatory interactions were consistently
maintained in colorectal cancer (Figure 3B).Strong association of the top 10 upstream TFs with the
survival of colon cancer patients
Now, we tested the utility of the upstream regulators
(TFMRA, TFMRA+SLR) as prognostic markers for colorec-
tal cancer. In the Moffit cohort (n = 177) used as the
training dataset, TFMRA and TFMRA+SLR showed a strong
differential expression pattern between good and poor
prognostic groups similar to the original 85 signature
genes (Figure 4A, 4B). An SVM (support vector machine)
classifier was constructed for TFMRA, TFMRA+SLR, and the
original 85 signature genes. For validation purposes, we
took the Melbourne cohort (n = 95) as an independent test
set. These 95 patients were classified into good or poor
prognostic groups independently from the use of each
of the three classifiers. For all three classifications, the
resulting good and poor prognostic groups showed the
same differential expression patterns in the test dataset
(Figure 4C, 4D, and 4E).
We compared the prognostic performance of the three
classifiers using the Kaplan-Meier plots for disease-free
survival (Figure 5). The upstream TFs showed a slightly
better or similar performance than the original 85 sig-
nature genes with the ordering of TFMRA+SLR > TFMRA >
85 signature genes. The p-values by log-rank test were
1.97×10-3 for TFMRA+SLR, 5.15×10
-3 for TFMRA, and
5.15×10-3 for the 85 signature genes. We further inspected
the prognostic performance over a range of signature
sizes for the gene signatures as well as the TF signatures
(Additional file 2: Figure S2). Overall, a stable prognostic






Figure 2 The transcriptional network between the top 10 TFs and the signature genes by MRA + SLR method. Node shape is triangular
for TFs and circle for target signature genes. Node color represents the log2 ratio of gene expression between the poor and the goop prognostic
group in the Moffit cohort (n = 177). Arrow shapes represent regulatory modes determined by the sign(+/−) of Spearman’s rank correlation
between a TF and its target gene. Edge color represents the magnitude of correlation.
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MRA and 7 ~ 21 TFs by MRA + SLR). Although the
best prognosis was observed for the gene signature of
size = 18 ~ 20, the TFs showed a reasonably good per-
formance comparable to the 85 signature genes using
the top 7–11 TFs by MRA + SLR and 10 ~ 19 TFs by
MRA. Notably, these upstream TFs were not selected
directly for good (or poor) survival but by the coverage
of known prognostic signatures in our regulatory network
model based purely on expression profiles. Therefore,
the performances of TFMRA and TFMRA+SLR are thought
to be unexpectedly high, considering that the signature
size dramatically decreased to less than 1/8 (from 85 to
10 genes) to demonstrate that upstream TFs can be even
better prognostic markers than the expression signatures.
The same strategy may be useful in identifying upstream
regulators for other types of cancer signatures such as
drug response and metastatic behavior.Candidate upstream regulators include many TFs involved
in tumorigenesis: HIF1A FOSL2, PLAGL2, ASCL2, and TCF7
Many of the upstream TFs for the prognostic signature
genes are actually well known regulators for various
tumorigenic processes such as cell invasion, metastasis,
and clinical outcome. Among the TFs of poor prognostic
effect, HIF1A and FOSL2 are examples of such cases.
Our network models also recapitulate some of the
known TF-target relations, as confirmed by the literature.
Hypoxia-inducible factors (HIFs) are the key regulators
of oxygen signaling pathway that respond to oxygen-
deficient environment known as hypoxia. Cancer cells
overcome hypoxic conditions by hypoxic pathway acti-
vated by HIFs. HIF1A is overexpressed in a variety of
human cancers and is associated with poor prognosis
in various cancers [15,16] including colon cancer [17].
Among the nine targets of HIF1A in our network by
MRA + SLR, the three interactions are confirmed by
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Figure 3 Correlation between the upstream TFs and their target genes. The average of the Spearman’s rank correlation coefficients was
calculated between each of the 13 TFs (union of TFMRA and TFMRA+SLR) and the low risk (left) or the high risk (right) signature genes for (A) Moffit
cohort and (B) Melbourne cohort.
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are involved in metastasis in renal cell carcinoma [18]
and hypoxia-induced metastasis [19], respectively. PTGS2
(known as COX2) is known to be directly up-regulated
by HIF1A and promotes hypoxia-induced angiogenesis
[20]. In addition, PTGS2 is shown negatively regulated
by ASCL2, one among the top 10 TFs in both networks.
FOSL2 (also known as FRA2) is a member of FOS family,
which encodes leucine zipper proteins forming AP-1
transcription factor complex together with JUN family
proteins. While FOSL2 is included in the top 10 TFs only
in TFMRA, its rank is still relatively high in TFMRA+SLR
(19th out of the 67 TFs). FOSL2 is known to mediate cell
growth and differentiation [21] and its transgenic mice
show a severe loss of small blood vessels in skin [22] to
suggest a role in angiogenesis. FOSL2 also activates LOX
in our network by MRA (Additional file 2: Figure S1).Among the TFs of good prognostic effect, PLAGL2 is
notable due to its dual functionality as proto-oncogene
and tumor suppressor. PLAGL2 has been known as a
proto-oncogene in acute myeloid leukemia (AML), glio-
blastoma (GBM), and colorectal cancer [23-25]. PLAGL2
can activate Wnt signaling that leads to leukemia in
mice [23] or suppression of cellular differentiation [25].
Contrarily, PLAGL2 also functions as tumor suppressor
that promotes apoptosis or arrests cell cycle [26-28].
ASCL2 and TCF7 (also known as TCF-1) are TFs activated
by Wnt signaling. ASCL2 is up-regulated in colorectal
adenocarcinoma [29] and, until recently, growth arrests
are observed by knockdown of ASCL2 in vivo [30];
although the prognostic effect of ASCL2 was positive
(+). TCF7 is a member of the TCF/LEF family, which
transmit the Wnt signal into the nucleus and activate Wnt
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Figure 4 Expression patterns of the selected marker genes between the good and the poor prognostic group. The distinct expression
pattern of (A) 85 signature genes and of (B) 13 TFs (union of TFMRA and TFMRA+SLR) are shown in the Moffit court (n = 177, training dataset).
Differential expression pattern is observed to be well maintained in an independent test dataset (Melbourne cohort, n = 95) for (C) the 85
signature genes, (D) TFMRA, and (E) TFMRA+SLR after class prediction.
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http://www.biomedcentral.com/1752-0509/7/86members of TCF/LEF family, TCF7 may act as negative
regulators for Wnt signaling because its isoforms lack a
β-catenin binding domain, while retaining Groucho in-
teraction domain necessary for repressor activity [31,32].
There is evidence that tumorigenic activity for other
TFs such as PRRX1 (PMX1) and SPDEF (PDEF). The
gene fusion between PRRX1 and NUP98 was reported
in AML [33]. Suppressive activities for metastasis, cell
growth, and migration are suggested for SPDEF [34,35].
Conclusions
We propose a genetic analysis pipeline to find transcrip-
tional modules for prognostic gene expression signaturesor other biomarkers. Our method only requires expression
profiles in the appropriate context such as tissue type or
disease condition. This procedure was applied to identify
key upstream regulators for the 85 prognostic signature
genes for colorectal cancer. To this end, a global tran-
scriptional network was constructed using the ARACNE
algorithm [9]. Candidate upstream regulators were se-
lected based on the number of signature genes as down-
stream targets or regulons (MRA step). An additional
filter was applied to extract only strong TF-target inter-
actions readily modeled by simple linear regression
(SLR step). As a result, we identified two sets of top 10









































































































Figure 5 The prediction performance of the selected prognostic markers. Kaplan-Meier plots for disease-free survival (DFS) are shown
between the good and the poor prognostic group for (A) the 85 signature genes, (B) TFMRA, and (C) TFMRA+SLR. P-value for difference between
two K-M plots was calculated by log-rank test.
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using a dataset independent of signature selection and
network modeling. These upstream TFs included many
known regulators for tumorigenic processes such as
metastasis and cell proliferation. The utility of our work
is two-fold. The first is that it allows the identification
of upstream regulators for a given set of signature genes
and provides leads to regulatory mechanisms. The second
is that these regulators may serve as better biomarkers
by themselves than the original signature with markedly
smaller sizes and better performance. The utility of our
method may be expandable to other types of signatures
such as diagnosis and drug response.
Methods
Data set
The 85 prognostic signature genes for colorectal cancer
were obtained from S-C Oh et al., which was derived by
mapping the 114 probes to the corresponding genes
[14]. The gene expression profiles from the Moffit co-
hort (GSE17536, n = 177) and those from the Melbourne
cohort (GSE14333, n = 95 after removal of redundancy)
were obtained from Gene Expression Omnibus database
(http://ncbi.nlm.nih.gov/geo). All the expression profiles
used were generated using Affymetrix HG-U133 Plus2.0
GeneChip array. The raw CEL files were processed and
normalized using the MAS5 method (affy package in R/
Bioconductor). The list of TFs was obtained from Carro
et al. [8] and includes 928 human TFs. These TFs were
mapped to 2155 probe sets in Affymetrix HG-U133
Plus2.0 GeneChip array.
Network inference using ARACNE
ARACNE (http://wiki.c2b2.columbia.edu/califanolab/index.
php/Software/ARACNE) was used to infer interactionsbetween the 2155 TF probe sets and their target genes.
The gene expression profiles of the Moffit cohort were
used in this analysis. Threshold for MI (mutual infor-
mation) and DPI (Data Processing Inequality) tolerance
were set to p < 0.05 (Bonferroni corrected for multiple
testing) and 0%, respectively. The bootstrapping option
was applied to generate 100 bootstrapped networks.
These networks were merged into a consensus network
from consensus voting methods based on a statistically
significant number of interactions inferred from the
bootstrapping steps. As probe sets in network were
mapped to genes, the consensus network was merged
into the gene level network.
Master regulator analysis
Fisher’s exact test was used to determine statistical
significance for overlaps between target genes in each
regulon. The FDRs for the p-values were computed
using procedures described by Benjamini and Hochberg
[36]. Then, the signature-enriched TFs were ranked by
signature coverage, which is the edge number linked
with signature genes.
Stepwise linear regression analysis
A linear model for each signature gene was constructed
as follows. The log2-expression level of TFs linked to
each signature gene was considered as the explanatory
variables. The log2-expression level of each signature
gene was considered as the response variable. Then, we
used stepwise algorithm in order to select the best min-
imal set of the explanatory variables in each model.
Akaike information criterion (AIC) was used as the stop
criterion. TFs with a p-value for linear regression coeffi-
cient that was less than 0.05 were removed in selected
variables.
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BRB-Array Tools (http://linus.nci.nih.gov/BRB-ArrayTools.
html) was used for building SVM classifier and class
prediction. The survival package in R was used for
Kaplan-Meier plot and log-rank test.
Additional files
Additional file 1: This file includes the list of the prognostic
signature genes of colorectal cancer, the list of all TFs selected by
MRA, detailed summary of prognostic effect of those TFs and the
edge list of the transcriptional network of the top 10 TFs by MRA
and MRA + SLR method.
Additional file 2: Figure S1. The transcriptional network between the
top 10 TFs and the signature genes by MRA method. Figure S2. The
influence of the signature size on the prognostic performance of the
gene signature (blue), TFMRA(green), and TFMRA+SLR(orange). The 85
signature genes were ordered by the fold change degree of differential
expression between the two groups in the original publication
publication [14]. The TFs were ordered by the coverage of the 85
signature genes in the regulons. The signature genes or TFs were
sequentially included by the corresponding order and the prognostic
performance was measured by p-values using Kaplan-Meier plot.
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